Popular search terms:
Search Results
117 results found-
Our Products | CSL Behring Australia
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products -
Products List
CSL Behring provides protein-based therapies for bleeding disorders, critical care, pulmonary disease, and other rare illnesses.
https://www.cslbehring.com.au/products/products-list -
Product Orders
CSL Behring Australia is a biopharmaceutical leader driven by its promise to save and improve lives. We manufacture remedies for rare and serious conditions.
https://www.cslbehring.com.au/product-orders -
Riastap Data Sheet
Resulting from these studies, as well as from long lasting clinical experience with fibrinogen products, dosage recommendations in the treatment of children are the same as for adults.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/riastap-nz-ds-v900-with-wfi.pdf -
Healthcare Portal | CSL Behring Australia
CSL Behring Australia's Healthcare Portal
https://www.cslbehring.com.au/healthcare-portal -
Australian PI . tradename (active ingredient)
Resulting from these studies, as well as from long lasting clinical experience with fibrinogen products, dosage recommendations in the treatment of children are the same as for adults.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/riastap-au-pi-v900.pdf -
Marketing Statement
CSL Behring Australia is a biopharmaceutical leader driven by its promise to save and improve lives. We manufacture remedies for rare and serious conditions.
https://www.cslbehring.com.au/marketing-statement -
Riastap Data Sheet
Resulting from these studies, as well as from long lasting clinical experience with fibrinogen products, dosage recommendations in the treatment of children are the same as for adults.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/nz-dss/riastap-nz-ds-800b.pdf -
PowerPoint Presentation
R&D Investor Briefing December 4, 2019 After struggling for years to get an accurate diagnosis, hereditary Legal Notice angioedema (HAE) patient Kathrin Schoen is working to ensure Forward looking statements the next generation of The materials in this presentation speak only as of the date of these materials, and include forward looking patients doesn't have statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, to wait so long. business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL.
https://www.cslbehring.com.au/-/media/shared/documents/7/rd-investor-briefing-2019.pdf -
Australian PI . tradename (active ingredient)
The potency of C1 esterase inhibitor is expressed in International Units (IU), which are related to the current WHO Standard for C1 esterase inhibitor products.
https://www.cslbehring.com.au/-/media/cslb-australia/documents/aus-pis-and-cmis/berinert-iv-au-pi-1000.pdf